Monte Rosa Therapeutics, Inc. GLUE Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$44.5M+3.5% | -$46.14M-70.4% | -$27.08M-120% | -$12.3M-126% | $46.89M— | ||
| $2.03M-2.8% | $2.09M-0.3% | $2.1M-1.4% | $2.13M+3.8% | $2.05M-0.6% | ||
| $5.95M+38.1% | $4.31M-1.3% | $4.36M-10.8% | $4.89M-7.6% | $5.3M+18.6% | ||
| $0— | —— | —— | —— | $59K— | ||
| $4.38M+141% | -$10.61M— | —— | -$1.1M+89.9% | -$10.87M-182% | ||
| -$3.71M-142% | $8.74M+108% | $4.19M+270% | -$2.47M+5.2% | -$2.61M-170% | ||
| $2.92M+312% | -$1.38M-46.2% | -$941K-155% | $1.71M+42,625% | $4K— | ||
| -$4.21M-200% | $4.22M-96.2% | $110.22M+580% | -$22.97M+72.6% | -$83.94M-194% | ||
| -$434K-45.6% | -$298K+15.8% | -$354K-146% | -$144K+49.1% | -$283K+37.3% | ||
| $9K— | $0-100% | $2.6M+170% | $961K-22.2% | $1.24M+393% | ||
| -$37.37M+13.1% | -$43.01M-143% | $100.43M+389% | -$34.72M+23.7% | -$45.49M-135% | ||
| $1.87M+144% | $767K+17.8% | $651K-61.6% | $1.7M+6.8% | $1.59M+767% | ||
| -$261M-301% | -$65.07M— | —— | —— | -$100.23M-224% | ||
| $4.52M-21.0% | $5.72M— | $0+100% | -$14K-200% | $14K-88.0% | ||
| —— | $357K— | $0— | —— | —— | ||
| $328.34M+1,008% | $29.62M+8,413% | $348K-4.7% | $365K+2,507% | $14K-97.7% | ||
| $29.97M+138% | -$78.46M— | —— | -$9.03M+93.8% | -$145.71M-248% | ||
| $2.03M-2.8% | $2.09M-0.3% | $2.1M-1.4% | $2.13M+3.8% | $2.05M-0.6% | ||
| -$3.71M-142% | $8.74M+108% | $4.19M+270% | -$2.47M+5.2% | -$2.61M-170% | ||
| -$7M— | —— | —— | —— | $0— | ||
| -$4.21M-200% | $4.22M-96.2% | $110.22M+580% | -$22.97M+72.6% | -$83.94M-194% | ||
| -$434K-45.6% | -$298K+15.8% | -$354K-146% | -$144K+49.1% | -$283K+37.3% | ||
| $9K— | $0-100% | $2.6M+170% | $961K-22.2% | $1.24M+393% | ||
| $2.92M+312% | -$1.38M-46.2% | -$941K-155% | $1.71M+42,625% | $4K— | ||
| —— | $1.75M0.0% | $1.75M0.0% | $1.75M0.0% | $1.75M— | ||
| $487K— | —— | —— | —— | $0— | ||
| $324.3M— | —— | —— | —— | $0— | ||
| $2.74M— | —— | —— | $146K-52.0% | $304K— | ||
| -$49K— | —— | -$235K+63.8% | -$650K-112% | -$307K— | ||
| -$434K-45.6% | -$298K+15.8% | -$354K-146% | -$144K+49.1% | -$283K+37.3% | ||
| —— | $0— | $0— | —— | —— | ||
| -$39.24M+10.4% | -$43.78M-144% | $99.78M+374% | -$36.42M+22.7% | -$47.08M-137% | ||
| -$39.24M+10.4% | -$43.78M-144% | $99.78M+374% | -$36.42M+22.7% | -$47.08M-137% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Monte Rosa Therapeutics, Inc. generate?
- Monte Rosa Therapeutics, Inc. (GLUE) generated -$14.7M in operating cash flow over the trailing twelve months.
- What is Monte Rosa Therapeutics, Inc.'s free cash flow?
- After $5.0M of capital expenditures, Monte Rosa Therapeutics, Inc.'s free cash flow was -$19.7M over the trailing twelve months, down 164.5% year over year.
- Where does Monte Rosa Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
